AstraZeneca– tag –
-
Daiichi Sankyo/AstraZeneca’s Datroway Receives US FDA Approval for First-Line Metastatic TNBC, EMA CHMP Gives Positive Opinion
Chemistry Today USA Overview Datroway (datopotamab deruxtecan), the TROP2-directed DXd ADC co-developed by Daiichi Sankyo and AstraZeneca, has received US FDA approval as a first-line treatment for unresectable or metastatic triple-negat... -
Pathos AI Licenses Alphamab’s First-in-Class TROP2/HER3 Bispecific ADC JSKN016 in $2.25 Billion Deal to Advance Breast Cancer Treatment
Fierce Biotech USA Overview Pathos AI has licensed JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) from Alphamab, in a deal worth up to $2.25 billion ($125 million upfront, $2.1 billion in milestones). JSKN0... -
Revolutionizing TNBC Treatment: Datroway ADC Gains EU Nod for Immunotherapy-Ineligible Patients
Precision Medicine Online European Union Overview AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), has received European Commission approval as a first-line monotherapy for patients with ... -
Daiichi Sankyo & AstraZeneca’s Datroway Approved in EU as Only TROP2-Directed Medicine with Overall Survival Benefit for 1st-Line Metastatic TNBC Patients Ineligible for Immunotherapy
Business Wire USA Overview Datroway, a TROP2-directed antibody-drug conjugate (ADC) by Daiichi Sankyo and AstraZeneca, received EU approval for first-line treatment of metastatic triple-negative breast cancer (TNBC) patients not eligible... -
Daiichi Sankyo & AstraZeneca’s Enhertu Plus Pertuzumab Recommended for EU Approval as 1st-Line Treatment for HER2-Positive Metastatic Breast Cancer, Achieves 44% Risk Reduction in Phase III
Daiichi Sankyo Press Release Japan Overview The EMA's CHMP has recommended Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for approval as a first-line treatment for HER2-positive metastatic breast cancer in the EU. This ... -
AI Accelerates Next-Gen Drug Design: From De Novo Protein Creation to Optimized Clinical Trials
SiTech Blog (MIT Technology Review analysis) USA Overview Artificial intelligence is revolutionizing drug discovery by enhancing every stage from protein structure prediction to clinical trial optimization. Generative models like RFdiffu... -
AI Transforms Drug Discovery: Generative AI Accelerates Molecule Design to Clinical Prediction, Reducing R&D Costs and Risks
World Pharma Today Unknown Overview AI, particularly generative AI, is fundamentally transforming drug discovery in 2026 by accelerating target identification, molecule design, and outcome prediction. AI-driven platforms computationally ... -
AstraZeneca/Daiichi Sankyo’s Enhertu Receives EU Approval as First Tumor-Agnostic HER2-Directed ADC
AstraZeneca UK Overview AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), has received EU approval as the first tumor-agnostic HER2-directed therapy for patients with previously treated HER... -
FDA Approves Multiple Novel Oncology Drugs in June 2026, Including ADC for Breast Cancer and Combination for Prostate Cancer
Targeted Oncology USA Overview In June 2026, the U.S. FDA granted several new drug approvals and expanded indications in oncology, notably for Gilead Sciences' antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), in two ... -
GLP-1 Market Heats Up with Oral Therapies and Triple Agonists for Obesity, Metabolic Health Opportunity Nears $150 Billion
DataM Intelligence USA Overview The GLP-1 market is experiencing intense competition, driven by the development of oral therapies and triple agonists for obesity and metabolic health, with the market opportunity projected to reach $150 b...
12